Michael L Wang Selected Research

Michael L Wang Research Topics

Disease

28	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2024 - 08/2013
17	Neoplasms (Cancer) 12/2023 - 08/2013
7	Multiple Myeloma 01/2021 - 01/2016
4	Disease Progression 01/2023 - 03/2016
3	B-Cell Lymphoma (Lymphoma, B Cell) 12/2023 - 09/2015
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2023 - 02/2015
3	Lymphoma (Lymphomas) 10/2023 - 07/2018
3	Hodgkin Disease (Hodgkin's Disease) 01/2019 - 01/2017
3	Infections 03/2016 - 08/2015
2	Residual Neoplasm 01/2022 - 07/2018
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 08/2013
2	Fatigue 01/2020 - 07/2019
2	Hematologic Neoplasms (Hematological Malignancy) 11/2016 - 03/2016
2	Hemorrhage 01/2016 - 08/2015
2	Lymphocytosis 01/2016 - 07/2015
1	Inflammation (Inflammations) 01/2023
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022
1	Neurologic Manifestations (Neurological Manifestations) 01/2020
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 11/2019
1	Anemia 07/2019
1	Second Primary Neoplasms (Neoplasms, Second) 11/2018
1	Autoimmune Diseases (Autoimmune Disease) 07/2018
1	B-Cell Leukemia (Leukemia, B Cell) 07/2018
1	Trophoblastic Neoplasms (Trophoblastic Tumor) 07/2017
1	Testicular Germ Cell Tumor 07/2017
1	Testicular Teratoma 07/2017
1	Teratoma (Teratoid Tumor) 07/2017
1	Rare Diseases (Rare Disease) 01/2017
1	Thromboembolism 03/2016
1	Peripheral Nervous System Diseases (PNS Diseases) 03/2016
1	Neutropenia 03/2016
1	Atrial Fibrillation 01/2016
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2015
1	Diarrhea 08/2015

Drug/Important Bio-Agent (IBA)

14	ibrutinibIBA 10/2022 - 08/2013
8	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023 - 08/2013
7	Rituximab (Mabthera)FDA Link 10/2022 - 01/2016
4	Bendamustine Hydrochloride FDA Link 10/2023 - 01/2021
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 10/2019
3	brexucabtagene autoleucelIBA 01/2024 - 01/2021
3	Chimeric Antigen ReceptorsIBA 10/2023 - 02/2015
3	Lenalidomide (CC 5013)FDA Link 01/2022 - 03/2016
3	Immune Checkpoint InhibitorsIBA 01/2020 - 07/2019
2	CyclinsIBA 12/2023 - 01/2022
2	pirtobrutinibIBA 01/2023 - 11/2022
2	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2022 - 01/2016
2	carfilzomibIBA 01/2021 - 10/2019
2	Thalidomide (Thalomid)FDA Link 12/2019 - 03/2016
2	LigandsIBA 07/2019 - 11/2016
2	Proteins (Proteins, Gene)FDA Link 05/2018 - 09/2015
2	Monoclonal AntibodiesIBA 01/2016 - 01/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2023
1	Peptidoglycan (Murein)IBA 01/2023
1	Vincristine (Oncovin)FDA LinkGeneric 01/2022
1	obinutuzumabIBA 01/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022
1	ChromatinIBA 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	acalabrutinibIBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021
1	Bortezomib (Velcade)FDA Link 01/2020
1	venetoclaxIBA 01/2020
1	filanesibIBA 10/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 07/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2018
1	Therapeutic UsesIBA 01/2018
1	Oxidoreductases (Dehydrogenase)IBA 12/2017
1	pyrimidineIBA 09/2017
1	TIC10 compoundIBA 11/2016
1	DNA (Deoxyribonucleic Acid)IBA 05/2016
1	Proteasome InhibitorsIBA 03/2016
1	Immunomodulating AgentsIBA 03/2016
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2016
1	daratumumabIBA 01/2016
1	elotuzumabIBA 01/2016
1	Cyclin D1IBA 01/2016
1	Bcl-2-Like Protein 11IBA 09/2015

Therapy/Procedure

20	Therapeutics 01/2023 - 08/2015
6	Drug Therapy (Chemotherapy) 01/2022 - 02/2015
2	Immunotherapy 01/2023 - 01/2020
2	Stem Cell Transplantation 01/2022 - 07/2018
1	Radiotherapy 01/2019